key: cord-0319109-dpw4wsbg
authors: Arifin, W. N.; Musa, K. I.; Hanis, T. M.; Rodzlan Hasani, W. S.; Che Nawi, C. M. N. H.; Ershad Ahmad Khan, E.; Suliman, M. A.; Termizi, S. A.; Ab Aziz, W. A.
title: A brief analysis of the COVID-19 death data in Malaysia
date: 2021-09-29
journal: nan
DOI: 10.1101/2021.09.28.21264234
sha: 9da84ef0bcad5b216b4e7f03324ec01d3db92db3
doc_id: 319109
cord_uid: dpw4wsbg

In December 2019, the first cases of Coronavirus Disease 2019 (COVID-19) were detected in Wuhan, China. Since then, COVID-19 begun to spread rapidly all over the world. On March 11, 2020, the World Health Organisation declared COVID-19 a pandemic. As of September 7, 2021, there were over 220 million confirmed COVID-19 cases globally, with more than 4.6 million deaths. Malaysia reported 2,067,327 confirmed cases with 22,743 deaths. Given the severity of the pandemic, the Ministry of Health Malaysia has stepped up in its efforts in handling the pandemic locally by sharing the COVID-19 related data on the GitHub, enabling transparent data sharing. This enables timely data analysis and quick decision to better understand the COVID-19 situation in this country. This article aims to provide a quick analysis of the death and vaccination data provided by the Malaysian Ministry of Health and to provide useful insight into the analysis.

In December 2019, the first penumonia cases of unknown origin -later identified Coronavirus Disease 2019 (COVID-19) -were detected in Wuhan, China. Since then, it begun to spread rapidly across mainland China and all over the world. On March 11, 2020, the World Health Organisation declared COVID-19 as a pandemic (1) . As of September 7, 2021, COVID-19 has infected over 220 million (226, 844, 344) people worldwide with more than 4.6 million (4,666,334) deaths (2). On the same day, Malaysia reported 2,067,327 confirmed cases with 22,743 deaths (3) . Numerous studies have shown that deaths related to have been linked to elderly, male, and various pre-existing conditions such as cardiovascular disease, diabetes, hypertension, respiratory disease, and hypertension (4-7).

Different countries have formulated different containment and mitigation strategies to combat this disease, including lockdowns and curfews while anxiously waiting for the arrival of definitive tool to fight this disease. Vaccine development was accelerated to achieve immunity to the virus and prevent transmission (8) . By mid-2021, 3 billion doses of the COVID-19 vaccine had been administered worldwide, with more than 40 million doses of the COVID-19 vaccine administered worldwide every day (9) . In Malaysia, vaccination coverage was selected as one of the key threshold indicators for the National Recovery Plan for COVID-19 pandemic (10).

On February 24, 2021, Malaysia launched its vaccination campaign against COVID-19. In the early phases, the campaign prioritised the at risk population; namely the healthcare workers and elderly with comorbidities after the approval for the use of the COVID-19 vaccines, Cominarty® (Pfizer-BioNTech) and CoronaVac® (Sinovac). Currently, the number of COVID-19 vaccines available in Malaysia has increased to five, including ChAdOx1-S (Oxford-AstraZeneca), Ad26.COV2-S® (Janssen) and Convidecia(TM) (CanSinoBio) (10). By September 17, 2021, around 55.5% of the total population has completed the vaccination and at least 66.6% of them have completed the first dose of vaccination (11,12).

The vaccination campaign has the potential to reduce the burden of COVID-19 in terms of morbidity and mortality if high vaccine intake is achieved. A previous study reported that the risk of COVID-19 infection, hospitalization and death was significantly reduced in vaccinated people (13) . However, the effectiveness of vaccination in lowering the death rate may vary depending on the type of COVID-19 vaccine.

With COVID-19 affecting mortality rapidly around the world, understanding and assessing the risks of death from COVID-19 infection through timely data analysis is critical. Traditional approaches previously used in research, such as extracting data from the electronic health record (HER), resulted in late reports resulting in delayed action. The timeliness in term of initial diagnosis to record, and record to report may vary from 6 months to 4 years respectively (14) . This is due to decentralized data management and sharing within and between ministries and other organizations. A novel approach by the Ministry of Health Malaysia by sharing the COVID-19 related data on the GitHub has enabled transparent data sharing. This will allow timely data analysis and quick decision to better understand the COVID-19 situation in this country. This article aims to provide a quick analysis of the death and vaccination data provided by the Malaysian Ministry of Health (11,15) and to provide useful insight into the analysis.

The data was sourced from MoH Malaysia's GitHub repository at https://github.com/MoH-Malaysia/ covid19-public/tree/main/epidemic/linelist as of Sep 28, 2021 (15) . The linelist_deaths.csv contains: is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

R version 3.6.3 was used. In general, tidyverse (16), gtsummary (17), broom (18) and knitr (19) R packages were used. We used quasipoisson regression to analyze the count data for deaths in all groups. Next, logistic regression with frequency weights were utilized, where we combined the death data with the vaccination data to utilize the number of completely vaccinated individuals in the model. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021.

The descriptive analysis of deaths among all reported cases (N = 25,935) is presented in Table 3 . Unvaccinated group reported the highest percentage of death with 18,133 (69.9%), followed by partially vaccinated and completely vaccinated groups with 5,846 (22.5%) and 1,956 (7.5%), respectively. The mean age for unvaccinated and partially vaccinated groups was lower than the completely vaccinated group, indicating more cases at relatively a younger age died in unvaccinated and partially vaccinated groups. The percentage with comorbid conditions for unvaccinated and partially vaccinated groups was lower than the completely vaccinated group, indicating more people without comorbid conditions died in unvaccinated and partially vaccinated groups. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; 

The descriptive analysis of deaths among the completely vaccinated cases (N = 1,956) is presented in Table 5 . Sinovac group reported the highest percentage of in-group death with 1,498 (76.6%), followed by Pfizer group with 439 (22.5%). AstraZeneca group reported the smallest number of deaths with 18 (0.9%) (see also Table 3 , Column 1, Complete). This descriptive analysis is followed by a detailed sub-group analysis. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264234 doi: medRxiv preprint vaccinated individuals. This was done to ensure that death in the data analysed occurred only after the cases completed the vaccination 14 days earlier.

Here, death rate is defined as:

where, in relation to Table 2 , the total number of completed vaccination per vaccine type was calculated from astra2, pfizer2, andsinovac2' variables. The death rate per 100,000 individuals is notably higher in the Sinovac group, followed by the Pfizer group. To determine the difference in death rate across the groups is significant statistically, we performed a weighted logistic regression, where we combined the death data with the vaccination data to utilize the number of completely vaccinated individuals in the model. The logistic regression was performed to determine whether vaccine type is associated with death. Again, we reiterate that we took the number of vaccinated individuals at 14 days earlier from the date of latest death among completely vaccinated individuals to ensure that death in the data analysed occurred only after the cases completed the vaccination 14 days earlier. The weighted logistic regression is presented in Table 7 . (Table 7) . These odds ratios indicate that Pfizer and Sinovac groups had higher odds of death as compared to AstraZeneca group. However, we suspected that this finding could be biased, because in the AztraZeneca group, the time between the first and second dose is typically eight weeks and above, so some deaths might have happened in between this period (see Table 3 , Column 2, Partial). So, we proceeded with another analysis which combined partially and completely vaccinated groups in the following section.

The descriptive analysis of deaths among the partially and completely vaccinated cases (N = 7,802) is presented in Table 8 . Sinovac group reported the highest percentage of in-group death with 4614 (59.3%), followed by Pfizer group with 2447 (31.5%). AstraZeneca group reported the smallest number of deaths with 715 (9.2%) (see also Table 3 , Column 1, Complete). This descriptive analysis is followed by a detailed sub-group analysis.

6 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; In this sub-group analysis, stratified death rates are calculated by vaccine type (Table 9 ). We took the latest number of vaccinated individuals as the denominator, because we no longer consider the completion of second dose as a criteria for the analysis. Here, death rate is defined as:

where, in relation to Table 2 , the total number of vaccination per vaccine type was calculated from astra1, pfizer1, and sinovac1 variables. Table 9 shows a different picture to that of Table 6 . The death rate per 100,000 individuals is highest in the AstraZaneca group, followed by the Sinovac group. Again, to determine the difference in death rate across the groups is significant statistically, we performed a weighted logistic regression, where we combined the death data with the vaccination data to utilize the number of vaccinated individuals in the model. The logistic regression was performed to determine whether vaccine type is associated with death.

The weighted logistic regression is presented in Table 10. 7 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; (Table 10) . These odds ratios indicate that Pfizer group had slightly lower odds of death (1.7 times lower) as compared to AstraZeneca group, while Sinovac group had slightly higher odds of death (1.4 times higher) as compared to AstraZeneca group. The advantage of Astrazeneca over the other two vaccines was diluted whenever we also included partially vaccinated individuals into analysis.

Based on these analyses, we concluded that:

1. Vaccination, either partial or complete, tremendously reduced the risk of death by 4.9 and 8.8 times respectively (Table 4 ). This was based on the analysis for all COVID-19 deaths (Section 3.1). 2. Vaccine type was found to be associated with the odds of death, where Pfizer and Sinovac had higher odds of death (3.5 and 10.2 odds ratio respectively) as compared to AstraZeneca (Table 7) . This was based on the analysis for completely vaccinated individuals (Section 3.2). However, we noted this could be attributed to the longer gap between first and second dose for AstraZeneca as compared to the other two vaccines. 3. Vaccine type was again found to be associated with the odds of death (Table 10) . However, in contrast to the result in (2), Pfizer and Sinovac instead showed 0.6 and 1.4 odds ratios respectively when the analysis was based on the data for both partially and completely vaccinated individuals (Section 3.3). This result indicates that Pfizer group had slightly lower odds of death (1.7 times lower), while Sinovac group had slightly higher odds of death (1.4 times higher) in comparison to AstraZeneca group. However, we noted the differences between the vaccine types were quite small in magnitude despite their statistical significance.

As of writing, there were several issues that limited our analyses. First, there was no line listing or per observation data for each vaccinated individuals. Although we had basic demographic information for the vaccinated death cases, the absence of information for the control group (vaccinated, alive) limited the logistic regression analysis to only the type of vaccine taken. Second, currently there was no line listing for each COVID-19 cases. The availability of this data will allow more insights into the associated factors of COVID-19 death.

Based on the findings, we clearly highlighted the advantage of COVID-19 vaccination in reducing the risk of death. Although there were advantages of choosing certain vaccines over others, these advantages negated each other when we took into account partial or complete vaccination status. In this respect, regardless of the vaccine type, getting vaccinated is the best way to protect against the risk of COVID-19 death.

8 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 29, 2021. ; https://doi.org/10.1101/2021.09.28.21264234 doi: medRxiv preprint

WHO. WHO director-general's opening remarks at the media briefing on COVID-19

who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 2. WHO. Coronavirus disease (COVID-19) pandemic. Numbers at a glance: Confirmed cases and confirmed deaths (last update

Situasi terkini COVID-19 di malaysia sehingga 17 SEPT 2021

OpenSAFELY: Factors associated with COVID-19 death in 17 million patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, china: A retrospective cohort study. The lancet

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Risk factors for mortality among COVID-19 patients. Diabetes research and clinical practice

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

COVID-19 vaccines

ANNEX_48_CLINICAL_GUIDELINES_FOR_COVID_IN_MALAYSIA_ of Health of Malaysia. Open data on malaysia's national covid-19 immunisation programme [Internet]. Ministry of Health of Malaysia

Vaksinasi COVID-19 malaysia

Pusat Pengajian Sains Perubatan

Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, italy

Surveillance evaluation of the national cancer registry in sabah, malaysia

Open data on COVID-19 in malaysia

Easily install and load the tidyverse

Gtsummary: Presentationready data summary and analytic result tables

Convert statistical objects into tidy tibbles

Knitr: A general-purpose package for dynamic report generation in r

Dynamic documents with R and knitr

Knitr: A comprehensive tool for reproducible research in R

We are grateful to the Ministry of Health of Malaysia (MoH) for their transparent data sharing initiative. This analysis would be not be possible without this data sharing initiative by the MoH. We also thank Dr. Shahnon Anuar Shahrani for proofreading the draft of this preprint.